Rapid Therapeutic Science Laboratories, Inc.: insider trades · United States · SEC (Form 4)

About Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. is a U.S.-based micro-cap issuer whose public-market profile has been shaped by multiple strategic pivots before settling on inhalation-based therapeutic technologies. The company was incorporated in the State of Nevada on February 22, 2013, originally as PowerMedChairs, later operated as Holly Brothers Pictures, Inc., and was renamed Rapid Therapeutic Science Laboratories, Inc. in January 2020 after adopting a new business strategy centered on potential commercial opportunities using licensed inhaler technology. For investors following SEC Form 4 insider activity, this is a highly speculative, low-liquidity name that should be viewed through the lens of a development-stage company rather than a diversified operating platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1575659/000139390520000203/rtsl_10k.htm)) Operationally, the company has described its business as focused on rapid application of therapeutics through aerosol and inhaler delivery systems. Public filings indicate that it began limited initial sales of inhaler products in early 2020, but that activity was subsequently suspended, with management citing the impact of COVID-19 and other contributing factors. As a result, the current business profile appears narrow and early stage, with limited evidence of sustained commercial scale. The company’s disclosures point to a small operating footprint and a lean structure rather than a mature pharmaceutical commercialization model. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/394441/content)) From a competitive standpoint, Rapid Therapeutic Science Laboratories does not appear to have a broad product portfolio or a well-established market franchise comparable with larger healthcare or pharma peers. Its competitive positioning is best described as a niche therapeutic-delivery concept with meaningful execution risk, including technology licensing dependence, regulatory sensitivity, and capital constraints. The company has also disclosed a very modest operating setup, including a relocation of office operations to De Leon, Texas in May 2023, underscoring the small scale of its corporate infrastructure. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/394441/content)) For investors in France, Belgium, and Switzerland, the key questions are whether the company can re-establish commercial traction, secure durable rights to its technology, and finance ongoing operations without excessive dilution. Historical filings show reliance on related-party advances and convertible debt, which are important context points when evaluating insider transactions reported on Form 4. In a name like this, insider buying or selling can attract attention, but the correct interpretation depends heavily on transaction size, liquidity, financing needs, and the company’s broader operational status. The issuer is a United States company and its SEC reporting framework makes insider filings a notable part of the investment case, yet the overall profile remains that of a very small, high-risk healthcare micro-cap. ([otcmarkets.com](https://www.otcmarkets.com/file/company/financial-report/394441/content))